Mikaela Hofer, Pharm.D., BSPS, BCCCP (@mikaelamhofer) identifies limitations of current vasopressor agents for the treatment of septic shock, reviews novel vasopressor therapies with a current or potential role in the management of septic shock and describes advancements in the development of biomarkers and pharmacogenomics for the monitoring and individualization of vasopressor treatment. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.